Nusano
  • Company
    • Leadership
    • Mission & Values
    • West Valley City
    • Contact Us
  • Technology
  • Life Sciences
    • Medical Isotopes
    • Request Quote
    • R&D Collaboration
    • Advisory Board
    • About Nuclear Med
  • Energy
    • HALEU
    • Nuclear Fuel Cycle
  • Industrial
  • Batteries
  • News
    • Press Releases
    • Video
    • Podcast
  • Careers
    • Current Openings
    • Life in Utah
Select Page
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

by Scott Larrivee | Jun 19, 2025 | News

Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies  DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

by Scott Larrivee | Jun 17, 2025 | News

Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors

Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors

by Scott Larrivee | Jun 11, 2025 | News, Utah

Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive...
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity

Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity

by Scott Larrivee | Jun 10, 2025 | News

Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June 10, 2025 – Nusano today announced it has successfully enriched gadolinium-160 (Gd-160) to 99.2% purity, a significant milestone demonstrating the...
Talk Radioisotopes: Sigal Kalmanson Cusnir, CEO and Co-Founder, Starget Pharma

Talk Radioisotopes: Sigal Kalmanson Cusnir, CEO and Co-Founder, Starget Pharma

by Scott Larrivee | May 29, 2025 | Podcast

In this episode of Talk Radioisotopes, host Scott Larrivee sits down with Sigal Kalmanson, CEO and Co-Founder of Starget Pharma, an early-stage company at the forefront of precision oncology. Starget is redefining the way radiopharmaceuticals are discovered and...
« Older Entries

Recent Posts

  • dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
  • Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals
  • Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors
  • Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity
  • Talk Radioisotopes: Sigal Kalmanson Cusnir, CEO and Co-Founder, Starget Pharma

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2025 Nusano | Web design
Privacy Policy – Terms of Service